Publication | Open Access
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
27
Citations
20
References
2021
Year
The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy-resistant and PD-L1-negative/low tumors.
| Year | Citations | |
|---|---|---|
Page 1
Page 1